Replimune Group, Inc. REPL R2KR3KPHARMA
Company Overview
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that expresses an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4. The company was founded in 2015 and is headquartered in Woburn, Massachusetts.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +195.48% |
| 6 Months: | +86.37% |
| 3 Months: | +58.82% |
| 1 Month: | +16.95% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)57.00 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | REPL Replimune Group, Inc. R2KR3KPHARMA | 15.04 | -4.76 | $1.26B | 0.00% | -116.69% | -107.88% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Jun 2022 | Sep 2022 | Dec 2022 | Jun 2023 | Sep 2023 | Dec 2023 | Jun 2024 | Sep 2024 | Dec 2024 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -3.18M | -4.26M | -4.73M | - | -5.88M | -7.10M | -10.14M | - | -10.91M | -12.24M | -16.66M | - | -17.83M | -19.66M | -20.27M | - | -27.38M | -29.25M | -29.70M | -40.88M | -41.58M | -41.63M | -55.65M | -63.83M | -56.54M | -57.37M | -58.92M | -66.02M | -90.42M | -84.29M | -71.87M |
| Net Income | -3.55M | -4.66M | -4.35M | -7.14M | -10.04M | -6.46M | -7.67M | -6.66M | -9.51M | -11.14M | -16.19M | -15.79M | -17.49M | -20.09M | -21.78M | -21.50M | -27.31M | -29.36M | -29.67M | -42.25M | -43.10M | -39.69M | -49.55M | -60.04M | -51.12M | -53.77M | -53.05M | -66.34M | -86.69M | -83.10M | -70.93M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | -0.44 | -0.46 | -0.44 | - | -0.53 | -0.56 | -0.57 | -0.78 | -0.79 | -0.69 | -0.75 | -0.90 | -0.77 | -0.78 | -0.68 | -0.79 | -0.95 | -0.90 | -0.77 |
| R&D Expense | 2.29M | 3.15M | 3.57M | - | 3.94M | 4.96M | 7.86M | - | 7.46M | 8.17M | 11.95M | - | 12.16M | 14.05M | 14.32M | - | 18.55M | 19.90M | 19.35M | 29.48M | 28.83M | 30.26M | 40.44M | 49.10M | 42.85M | 42.97M | 43.45M | 48.00M | 57.84M | 57.88M | 53.14M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | -9.65M | -19.23M | -30.95M | -56.20M | -79.95M | -118.31M | -177.08M | -234.77M | -261.63M | -319.92M |
| Net Income | -7.70M | -19.70M | -30.83M | -52.62M | -80.87M | -118.04M | -174.28M | -215.79M | -247.30M | -313.94M |
| Diluted EPS | - | - | - | - | -1.75 | -2.26 | -2.99 | -3.24 | -3.07 | -3.38 |
| R&D Expense | 6.94M | 13.52M | 22.17M | 38.76M | 56.75M | 79.55M | 126.53M | 174.96M | 189.45M | 221.18M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 65.15M | 154.33M | 234.10M | 543.10M | 461.19M | 646.59M | 487.72M | 551.33M | 332.39M |
| Total Equity | -11.52M | -28.07M | 137.86M | 183.72M | 498.73M | 411.23M | 555.29M | 374.51M | 415.84M | 166.16M |
| Cash & Equivalents | - | 17.58M | 25.70M | 59.50M | 182.52M | 105.95M | 146.59M | 74.46M | 111.12M | 209.02M |
| Long Term Debt | - | - | - | 9.80M | - | 0 | 28.65M | 44.81M | 46.38M | 83.31M |
| Total Liabilities | - | 6.86M | 16.47M | 50.38M | 44.37M | 49.96M | 91.30M | 113.21M | 135.49M | 166.23M |
| Current Liabilities | - | 5.16M | 9.88M | 11.87M | 14.55M | 20.76M | 33.83M | 40.44M | 62.36M | 58.23M |
Cash Flows (Annual)
Figures in USD.
| Metric | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -7.08M | -16.01M | -25.38M | -60.55M | -61.39M | -82.18M | -128.05M | -185.47M | -192.25M | -280.34M |
| Investing Cash Flow | -238.00K | -44.05M | -65.94M | -5.23M | -188.78M | -1.81M | -142.50M | 97.20M | -23.80M | 310.84M |
| Financing Cash Flow | 15.00M | 54.75M | 101.39M | 100.17M | 372.46M | 6.60M | 311.30M | 16.28M | 252.40M | 66.29M |
| Capital Expenditure | -238.00K | -136.00K | -2.60M | -6.54M | -2.39M | -2.34M | -2.27M | - | - | - |
| Free Cash Flow | -7.32M | -16.15M | -27.98M | -67.09M | -63.78M | -84.52M | -130.32M | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - | - | - | - |
| ROE % | 66.9% | 70.2% | -22.4% | -28.6% | -16.2% | -28.7% | -31.4% | -57.6% | -59.5% | -188.9% |
| ROCE % | - | -32.1% | -21.4% | -25.3% | -15.1% | -26.9% | -28.9% | -52.5% | -53.5% | -116.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Baker Bros. Advisors, LP | 11.78% | 11.05M | $171.20M |
| 2 | Blackrock Inc. | 9.55% | 8.96M | $138.86M |
| 3 | RTW Investments LP | 7.90% | 7.41M | $114.88M |
| 4 | Ridgeback Capital Investments L.P. | 7.79% | 7.31M | $113.32M |
| 5 | Goldman Sachs Group Inc | 4.84% | 4.54M | $70.39M |
| 6 | State Street Corporation | 4.73% | 4.44M | $68.82M |
| 7 | Montanova Capital LLC | 4.68% | 4.39M | $68.04M |
| 8 | Boxer Capital Management, LLC | 4.25% | 3.98M | $61.74M |
| 9 | Vanguard Capital Management LLC | 3.09% | 2.90M | $44.89M |
| 10 | FCPM III Services B.V. | 2.99% | 2.81M | $43.53M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for REPL
Replimune to Present at the Cantor Global Healthcare Conference 2026
WOBURN, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members of the Replimune ma…
Why Did SJM, REPL, NEO Stocks Surge To 52-Week Highs Today?
Earnings, drug development, and healthcare reimbursement fueled the stock rallies.
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WOBURN, Mass., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity aw…
Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update
TUDRIQEV™ in combination with nivolumab receives FDA accelerated approval and will launch within 60 days Michelle DiNapoli appointed as Chief Commercial Officer Recently completed financing extends cash runway to support commercial launch a…
Replimune Group (REPL) Wins FDA Approval For Advanced Melanoma Treatment
Replimune Group (NasdaqGS:REPL) received FDA accelerated approval for TUDRIQEV (RP1) in combination with nivolumab to treat advanced cutaneous melanoma after anti PD 1 therapy. This marks the first FDA approval for Replimune and follows an …
REPL Stock Hits Near 18-Month High On Pricing Of $150M Offering – But, Retail Sees Share Price ‘Unwinding Over Time’
The firm priced about 9.7 million shares at $12.06 each, in line with Friday’s closing price.
REPL — Frequently Asked Questions
What is the current share price of Replimune Group, Inc. (REPL)?
As of 2026-09-07 16:24 PDT, Replimune Group, Inc. (REPL) trades at $15.04 on NasdaqGS. Its 52-week range is $1.70 to $15.98.
What is the market capitalisation of REPL?
Replimune Group, Inc. (REPL) has a market capitalisation of $1.26B on NasdaqGS.
What is the P/E ratio of REPL?
REPL trades at a trailing price-to-earnings (P/E) ratio of -4.76. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 6.00.
What is the return on equity (ROE) of REPL?
REPL has a return on equity (ROE) of -107.88%. Its return on capital employed (ROCE) is -116.69%.
Is REPL a good stock to buy?
This page provides a data-driven analysis of Replimune Group, Inc. (REPL), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.